SCHEMBL16634805

SCHEMBL16634805

COC(=O)c1ncc(Cl)cc1Br

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.49
NPSR1 Q6W5P4 1/20 0.41
ALDH1A1 P00352 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
PLAU P00749 1/20 0.40
S1PR4 O95977 1/20 0.38
OPRK1 P41145 1/20 0.38
MEN1 O00255 1/20 0.38
RECQL P46063 1/20 0.38
KMT2A Q03164 1/20 0.38
KDM4E B2RXH2 3/20 0.37
ABL1 P00519 1/20 0.37
POLB P06746 2/20 0.36
MAPT P10636 2/20 0.36
MAPK1 P28482 2/20 0.36
GMNN O75496 1/20 0.36
LMNA P02545 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31006673 1.00 PTPN1 (0.49) PTPN1NPSR1ALDH1A1L3MBTL1PLAU
SCHEMBL29796660 0.82 S1PR4 (0.46) NPSR1ALDH1A1L3MBTL1S1PR4OPRK1
SCHEMBL1420843 0.82 S1PR4 (0.46) NPSR1ALDH1A1L3MBTL1S1PR4OPRK1
SCHEMBL6057160 0.82 NPSR1 (0.43) NPSR1OPRK1KMT2AMAPK1TSHR
SCHEMBL31306162 0.82 GABRA1 (0.39) PTPN1PLAUGABRA1GABRG2GABRB3
SCHEMBL17978199 0.81 MAPK1 (0.51) NPSR1ALDH1A1L3MBTL1KMT2AKDM4E
SCHEMBL26910332 0.81 NPSR1 (0.42) PTPN1NPSR1ALDH1A1KMT2AKDM4E
SCHEMBL1915284 0.81 ATM (0.47) NPSR1ALDH1A1L3MBTL1OPRK1KDM4E
SCHEMBL10314919 0.81 NPSR1 (0.42) NPSR1L3MBTL1KDM4EPOLBMAPK1
SCHEMBL31255330 0.79 ALDH1A1 (0.44) NPSR1ALDH1A1L3MBTL1S1PR4OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022114-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE GILEAD SCIENCES, INC. 2026-01-22 US disclosed
US-12441726-B2 Compounds and uses thereof FOGHORN THERAPEUTICS, INC. (US) 2025-10-14 US disclosed
EP-4594316-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE Repare Therapeutics Inc. (CA) 2025-08-06 EP disclosed
EP-4419525-B1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LTD (GB) 2025-07-23 EP disclosed
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2025-07-17 US disclosed
US-20250026748-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA REPARE THERAPEUTICS INC. (CA) 2025-01-23 US disclosed
CN-113874363-B Protein tyrosine phosphatase inhibitors ARRAY生物制药公司 2024-11-12 CN disclosed
WO-2024218499-A1 HETEROCYCLIC INHIBITORS OF DNA POLYMERASE THETA FOR THE TREATMENT OF CANCER ARTIOS PHARMA LIMITED (GB) 2024-10-24 WO disclosed
WO-2024197401-A1 1,3,4-THIADIAZOL-2-YL CARBOXAMIDE AND 1,3-THIAZOL-2-YL CARBOXAMIDE COMPOUNDS AND USES THEREOF AS INHIBITORS OF HUMAN POLYMERASE THETA REPARE THERAPEUTICS INC. (CA) 2024-10-03 WO disclosed
EP-4419525-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER Artios Pharma Limited (GB) 2024-08-28 EP disclosed
US-20200317665-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2020-10-08 US disclosed
US-10239863-B2 Factor XIa inhibitors MERCK SHARP & DOHME CORP. (US) 2019-03-26 US disclosed
US-20180179180-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2018-06-28 US disclosed
US-20180179180-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2018-06-28 US disclosed
US-20160257668-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2016-09-08 US disclosed
US-20160257668-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2016-09-08 US disclosed
US-20160257668-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2016-09-08 US disclosed
EP-3054944-A1 FACTOR XIa INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 EP disclosed
WO-2015054087-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed
WO-2015054087-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022114-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE POLK, POLQ, POLB PTPN1 2879/4885NPSR1 4413/4885ALDH1A1 3422/4885
US-20250026748-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA POLA1, POLL, POLD1 PTPN1 1331/4885NPSR1 1516/4885ALDH1A1 789/4885
US-20180179180-A1 Factor XIa Inhibitors F11, SERPINC1, TFPI PTPN1 3604/4885NPSR1 3358/4885ALDH1A1 3635/4885
US-20200317665-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS PPM1A, PPM1F, PPP5C PTPN1 5/4885NPSR1 2977/4885ALDH1A1 1829/4885
US-20160257668-A1 Factor XIa Inhibitors F11, SERPINC1, TFPI PTPN1 3604/4885NPSR1 3358/4885ALDH1A1 3635/4885
US-12441726-B2 Compounds and uses thereof VHL, CLN6, TFEB PTPN1 4436/4885NPSR1 4599/4885ALDH1A1 2571/4885
US-10239863-B2 Factor XIa inhibitors F11, SERPINC1, TFPI PTPN1 3604/4885NPSR1 3358/4885ALDH1A1 3635/4885
US-20250230165-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER NQO1, VHL, SDHA PTPN1 3404/4885NPSR1 3492/4885ALDH1A1 174/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.